POS0970 SAME OR DIFFERENT? ANALYSIS OF SIMILARITIES AND DIFFERENCES OF CROHN’S DISEASE AND ULCERATIVE COLITIS IN SPONDYLOARTHRITIS: AN ANCILLARY ANALYSIS FROM THE WORLDWIDE ASAS-perSpA STUDY.

Background Crohn’s disease (CD) and ulcerative colitis (UC) are grouped as inflammatory bowel (IBD), both frequently found extra-musculoskeletal manifestations in spondyloarthritis (SpA). Several studies have described the connection between SpA IBD directions. Still until today, no investigated possible differences musculoskeletal two main entities of disease: CD UC. Objectives To evaluate clinical characteristics associated with presence or UC patients from international cross-sectional ASAS-perSpA study. Methods We analyzed 3152 ASAS per-SpA cohort who had a diagnosis axial peripheral according to treating rheumatologist. Patients - confirmed by endoscopy were identified stratified which their was not specified, excluded. Demographics, characteristics, treatments patient-reported outcomes compared subgroups. Results Among 146 diagnosed included analysis, 87 (59.6%) presented (75 12 SpA) 39 (26.7%) (34 5 Figure 1. A total 20 (13.7%) excluded, due an inconclusive IBD. similar age (44.9 vs 44.0 years old) sex distribution, although slightly higher frequency males observed than (63.2% 51.3%). The diagnostic delay for 7.0 8.1 did find groups related any such chronic back pain, uveitis, arthritis, enthesitis dactylitis (Table 1). only parameter showing significant difference Bath Ankylosing Spondylitis Functional Index (BASFI) mean score 3.3 2.2 respectively (p=0.02) showed tendency be HLA-B27 positive (51.9% vs. 39.4% UC), but this reach statistical significance. No regarding treatment patterns groups. Table Demographics concomitant (n=146). Disease N=87 Ulcerative Colitis N=39 P Age, (SD) 44.9 (13.5) (13.0) 0.68 Sex, n/N (%) male 55/87 (63.2) 20/39 (51.3) 0.21 Smoker ever, 36/87 (41.4) 19/39 (48.7) 0.44 Diagnostic (years), (6.9) 8.8 (8.1) 0.38 Psoriasis 9/87 (10.3) 6/39 (15.4) 0.47 Uveitis 17/87 (19.5) 11/39 (28.2) 0.28 Synovitis 42/87 (48.3) 18/39 (46.2) 0.83 Enthesitis 26/87 (29.9) 14/39 (35.9) 0.50 Dactylitis 3/87 (3.4) 1/39 (2.6) 0.79 Axial involvement ever (according rheumatologist), 79/87 (90.8) 37/39 (94.9) Sacroiliitis on X-ray, 64/87 (73.6) 26/39 (66.7) 0.19 positive, 28/54 (51.9) 13/33 (39.4) 0.26 CRP mg/L, 11.1 (33.8) 15.3 (30.1) 0.13 ASDAS-CRP, 2.4 (1.0) (1.1) 0.84 BASFI, 0-10 (2.1) 0.02 csDMARDs 71/87 (81.6) 35/39 (89.7) 0.25 bDMARDs 72/87 (82.8) 33/39 (84.6) 0.80 ASDAS, Activity Score; Index; bDMARD, biological disease-modifying antirheumatic drugs; CRP, c-reactive protein; csDMARD, conventional synthetic SD, standard deviation; SpA, spondyloarthritis. Conclusion In our ancillary analysis study UC, presentation demographic subgroups observed, except BASFI. Disclosure Interests None declared